Research Analysts Offer Predictions for ARTV Q1 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share estimates for Artiva Biotherapeutics in a report issued on Monday, March 24th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.62) per share for the quarter. Wedbush has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.54) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.95) EPS.

Several other research analysts also recently issued reports on ARTV. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday. Finally, Cantor Fitzgerald reduced their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Stock Down 10.7 %

Shares of Artiva Biotherapeutics stock opened at $3.16 on Thursday. The firm’s fifty day simple moving average is $4.71 and its 200-day simple moving average is $9.23. Artiva Biotherapeutics has a 12 month low of $3.15 and a 12 month high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the third quarter valued at about $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $52,000. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares during the period. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. acquired a new position in Artiva Biotherapeutics during the third quarter worth $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.